Background: Current therapy for PDAC is modestly effective. Therapy selection guidelines are typically limited to single aberrations and ignore relevant patient-specific omics. These alterations create patient-specific resistance pathways that cancer cells use to resist one-mutation one-drug Physician Choice therapies. Singula™ utilizes the novel Cellworks Omics Biology Model (CBM), which predicts patient-specific biomarker and phenotype response of a personalized diseased cell to drug agents, radiation and cell signaling. We test the hypothesis that Singula is a more accurate predictor of patient-specific therapy response to targeted agents compared to Physician Choice. Methods: The performance of the Singula Classifier of patient therapy response was evaluated in an independent retrospective cohort of N = 52 Stage I - IV PDAC patients aged 35-85, whose omics data were included in TCGA and ICGC.